LunG and Melanoma canceR pAtients coVId19 Disease (GRAVID)

This is a multi-centre study on lung cancer patients which experienced COVID-19. Information on clinical features, clinical course, management and outcomes will be collected for both, thoracic cancers and COVID-19 infection. Firstly, investigators will be registered in an online secure registry. After that, a protocol will be developed in order to collect clinical data for the research. It will also include I on the care organization or the perception of the patient and their family members.

The final stage will consist on retrospective data collection from patients. So, it is a retrospective study data collection, preceded by prospective data registry.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Cancer Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Respiratory Tract Neoplasms Thoracic Neoplasms Virus Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Complejo Hospitalario Universitario de Ferrol, Ferrol, A Coruña, Spain

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients diagnosed with lung cancer
Patients who have contracted COVID-19 infection

Exclusion criteria

Patients diagnosed with lung cancer but no confirmation of COVID-19 infection.

Treatment and study plan

Primary outcomes

Clinical data of lung cancer patients with COVID-19 diagnoses

Time frame: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 years

Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as clinical data.
Diagnosis data

Time frame: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 years

Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as data about diagnosis
Treatments received

Time frame: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 years

Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as treatments received
Prognostic factors

Time frame: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 years

Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as prognostic factors.

Sponsors and collaborators

Lead sponsor

Spanish Lung Cancer Group

Other

Registry information

Official study title

Observational Retrospective Register of Spanish Lung and Melanoma Cancer Patients With COVID19 Disease

Acronym: GRAVID

Important dates

Study start: 2020
Primary completion: 2021
Study completion: 2021
First posted: Apr 14, 2020
Registry last updated: Jun 27, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed